Corbus Pharmaceuticals' Obesity Drug CRB-913 Shows Promising Weight Loss in Phase 1b Trial — Corbus Pharmaceuticals Holdings, Inc.

Event summary

Corbus Pharmaceuticals' CRB-913 achieved a mean weight loss of 5% at the 60 mg dose after 12 weeks in the CANYON-1 Phase 1b trial.
The study enrolled 254 obese, non-diabetic adult participants across 15 U.S. sites.
CRB-913 demonstrated a favorable safety profile with fewer gastrointestinal adverse events compared to oral GLP-1 drugs.
The company plans to present detailed data at ObesityWeek® 2026 and initiate a Phase 2 study in the first half of 2027.

The big picture

Corbus Pharmaceuticals' positive Phase 1b data for CRB-913 positions the drug as a potential new class of oral, non-incretin obesity medicines. The results are particularly notable given the growing demand for alternatives to GLP-1 receptor agonists, which often come with tolerability issues. The obesity drug market is rapidly expanding, with global sales projected to exceed $100 billion by 2030, driven by the increasing prevalence of obesity and the need for effective, well-tolerated treatments.

What we're watching

Regulatory Pathway: Whether the FDA will support an accelerated approval path for CRB-913 given its novel mechanism of action.
Competitive Positioning: How CRB-913's emerging GI tolerability profile will compare to existing oral GLP-1 drugs in the market.
Combination Therapy: The potential for CRB-913 to be combined with GLP-1 therapy, expanding its market opportunity.